Preferred Label : Krabbe disease;
Symbol : KRB;
CISMeF acronym : GCL; GLD;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : GCL; Globoid cell leukodystrophy; GLD; Globoid cell leukoencephalopathy; Galactosylceramide beta-galactosidase deficiency; Galc deficiency; Galactocerebrosidase deficiency;
Description : Krabbe disease is an autosomal recessive lysosomal disorder affecting the white matter
of the central and peripheral nervous systems. Most patients present within the first
6 months of life with 'infantile' or 'classic' disease manifest as extreme irritability,
spasticity, and developmental delay (Wenger et al., 2000). There is severe motor and
mental deterioration, leading to decerebration and death by age 2 years. Approximately
10 to 15% of patients have a later onset, commonly differentiated as late-infantile
(6 months to 3 years), juvenile (3 to 8 years), and even adult-onset forms. The later-onset
forms have less disease severity and slower progression. These later-onset patients
can be clinically normal until weakness, vision loss and intellectual regression become
evident; those with adult onset may have spastic paraparesis as the only symptom.
Disease severity is variable, even within families (summary by Tappino et al., 2010).;
Inheritance : Autosomal recessive;
Molecular basis : Caused by mutations in the glycosylceramidase gene (GALC, 606890.0001);
Laboratory abnormalities : Elevated cerebrospinal fluid (CSF) protein; Galactocerebroside beta-galactosidase deficiency in serum, leukocytes, and fibroblasts;
Prefixed ID : #245200;
Origin ID : 245200;
UMLS CUI : C0023521;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
Genes related to phenotype
HPO term(s)
Narrower ORDO disease(s)
ORDO concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT